Tanflex

Quick links to important sections

Tanflex

Method of action: Local Anesthetic, Stomatological

Treatment option: Bacterial Vaginosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanflex

Property Description
Active Ingredient Benzydamine hydrochloride
Form Topical (Oral spray, mouthwash/gargle solution, lozenges)
Pharmacological Class Atypical NSAID and Local Anesthetic
General Purpose Symptomatic relief of localized inflammation and pain
Origin Synthetic compound (Indazole derivative)

Defining Tanflex: Identity and Pharmacological Class

Tanflex is a medicinal preparation whose active ingredient is Benzydamine hydrochloride, a synthetic chemical compound used for localized treatment. Benzydamine is an atypical Nonsteroidal Anti-inflammatory Drug (NSAID) that also acts as a local anesthetic. This dual-action nature—addressing inflammation while simultaneously providing numbing—is utilized for managing discomfort in mucosal tissues. Structurally, Benzydamine is an indazole derivative, which gives it unique properties compared to conventional systemic NSAIDs.

Composition, Forms, and General Therapeutic Purpose

The Benzydamine in Tanflex is formulated exclusively for topical administration, ensuring the therapeutic concentration is delivered directly to the area of concern, such as the lining of the mouth or throat. It is available in diverse preparations, including oral spray, mouthwash or gargle solution, and lozenges, with Benzydamine hydrochloride serving as the single active ingredient. The general therapeutic purpose of these products is to provide focused, symptomatic relief for painful, inflamed areas, such as simple throat irritation. Benzydamine is intended for anti-inflammatory and pain-relieving use in these topical oral applications. The formulation’s design prioritizes coverage and penetration of the mucosal surfaces to provide its local benefits.

What side effects are possible with Tanflex?

Official Regulatory Safety Profile

The safety profile of Benzydamine hydrochloride (Tanflex) is formally documented in government regulatory sources, which classify adverse reactions primarily by frequency and the body system affected. Since this medicine is for local application, the effects are mostly concentrated at the application site.

Adverse Reactions by Frequency and System

Official regulatory documents classify adverse reactions according to the following frequency patterns:

  • Uncommon: This category includes local effects such as hypoesthesia (local numbness in the mouth/throat), a local stinging sensation, and photosensitivity reactions.
  • Very Rare: Documented very rare systemic effects include laryngospasm, bronchospasm, and angioedema.
  • Frequency Not Known: This category lists serious systemic reactions, including anaphylactic reaction and generalized hypersensitivity reactions.

Adverse effects are documented across several System-Organ Classes, including Immune System Disorders, Respiratory Disorders, Skin Disorders, and Gastrointestinal Disorders.

Serious Reactions and Specific Safety Considerations

The official label documents serious adverse reactions, notably the potential for anaphylactic reaction and bronchospasm. Specific safety constraints apply to certain patient groups:

  • Cross-Sensitivity: Caution is applied in individuals with a history of hypersensitivity to other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or acetylsalicylic acid.
  • Asthma: The risk of bronchospasm is specifically noted as a concern for patients with a history of bronchial asthma.
  • Long-Term Use: Regulatory texts state that prolonged application may be associated with an increased risk of local allergic reactions or sensitization.

These official statements structure the risk profile, balancing the common local effects with the formal documentation of rare, but clinically important, systemic reactions, particularly for susceptible individuals.

Overdose and Emergency Response

The regulatory profile for topical Benzydamine hydrochloride states that the risk of adverse systemic effects or overdose is negligible when the product is used locally and correctly. Overdose is only expected in the scenario of accidental ingestion of large quantities of the concentrated solution, which significantly exceeds the intended topical dose.

Official Signs and Manifestations

Overdose manifestations primarily affect two systems:

  • Central Nervous System (CNS): Documented symptoms include dizziness, hallucinations, agitation, anxiety, and irritability. Severe outcomes associated with higher systemic doses include the potential for seizures (convulsions), excitation, and tremor.
  • Gastrointestinal (GI): Signs are nausea, vomiting, abdominal pain, and oesophageal irritation.

Required Emergency Actions

Government regulatory documents mandate that users must seek immediate medical help or contact a doctor or pharmacist immediately for advice if they take too much or accidentally swallow large quantities.

Management and Observation

  • Treatment: In acute overdose, only symptomatic and supportive treatment is possible.
  • Antidote: No specific antidote is known for Benzydamine hydrochloride.
  • Observation: Patients who have experienced an overdose must be kept under close observation and adequate hydration should be maintained.

Therapeutic Uses of Tanflex

Quick Facts

  • Relief of Discomfort: May help provide localized relief for conditions causing pain in the mouth and throat.
  • Addressing Inflammation: Used as a local treatment for inflammatory states involving the pharynx, mouth, and gums.
  • Oral Health Support: Utilized for managing symptoms associated with gum tissue issues and certain dental procedures.

Tanflex (benzydamine) is a medication utilized for the temporary, localized relief of symptoms associated with painful inflammatory conditions of the mouth and throat. It is typically employed to help manage discomfort and inflammation of the oral mucosa, pharynx, and gums. The primary therapeutic use is to address pain, irritation, and swelling in these areas.

This agent is considered a non-steroidal compound intended for topical application. It works to support symptom management for conditions such as sore throat, inflammation of the gums (gingivitis), and irritation due to specific dental or surgical procedures in the oral cavity. Its applications include helping to ease swallowing difficulties caused by inflammation, thereby supporting the restoration of normal function.

Additional uses include oral inflammatory lesions (mucositis) that may be related to certain medical treatments.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tanflex — Official Regulatory Information

This section outlines population eligibility rules for topical Tanflex (Benzydamine) formulations based strictly on governmental regulatory documents.

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known hypersensitivity to benzydamine hydrochloride or to any of the excipients must not use the medicine.
Age-related eligibility rules Adults and Older Adults are generally eligible. Use in children is formulation-dependent: mouthwash is often not recommended for those leq 12 years, while lozenges and sprays have specific minimum age thresholds (6 years or 12 years).
Pregnancy and lactation eligibility status Use is generally not recommended during pregnancy or lactation due to limited or insufficient regulatory data; use is conditional on physician assessment.
Eligibility-related restrictions Caution is mandated for patients with current or previous history of bronchial asthma, as bronchospasm may be precipitated. Use is also not advisable in patients with hypersensitivity to aspirin or other NSAIDs.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use topical Benzydamine by establishing absolute contraindications linked to hypersensitivity and strict age limitations that prohibit or restrict use in younger children based on the product type. Furthermore, a conditional use status is applied to pregnant, breastfeeding, and asthmatic patients, reflecting regulatory caution due to the lack of established safety data in these specific populations.

What should I know about interactions with other medicines?

The regulatory documentation for Tanflex (Benzydamine hydrochloride) outlines an interaction profile characterized by minimal systemic risk. Because this medicine is formulated exclusively for topical use as a mouthwash, spray, or lozenge, its systemic absorption into the bloodstream is very low. Consequently, regulatory authorities report a general absence of known, clinically significant systemic drug interactions. The official prescribing information, therefore, does not list any specific medicines that are formally contraindicated for co-administration based on a systemic interaction risk.

No systemic interaction mechanisms, such as those involving the cytochrome P450 (CYP) enzymes or drug transporters, are described in the official labels. Regulatory documents do not identify any substances that would alter the plasma concentration or clearance of Benzydamine, nor do they impose mandatory timing separation rules for co-administering this product with other medicines.

The only specific constraint noted in the official interaction profile relates to non-pharmaceutical products:

  • Herbal Products and Supplements: Regulatory sources include a caution that the safety of co-administration with herbal remedies or dietary supplements has not been definitively established due to a lack of specific interaction data.

This structure reflects the localized action of the medicine, which limits the potential for the systemic drug-drug interactions that are commonly documented for orally absorbed agents.

Mechanism of Action

the final 100-200 word mechanistic markdown text with NO links

Pharmacodynamic Mechanism of Action

The action of Tanflex, driven by its active component, Benzydamine, operates through three primary peripheral mechanisms. The molecule functions as a membrane stabilizer by integrating with the phospholipid bilayers of immune cells, inhibiting the discharge of destructive lysosomal enzymes and mitigating the synthesis and release of pro-inflammatory messengers, including TNF-alpha and IL-1beta. This interaction contributes to limiting the initial cascade of the inflammatory response and modulates local physiological signaling within the affected tissue.

Additionally, the drug affects vascular dynamics by modulating capillary permeability, thereby influencing the movement of fluid and cells across the microvasculature. Concurrently, it interferes with sensory nerve impulse transmission via the non-selective blockade of voltage-gated sodium channels found in peripheral nerve endings. This action prevents the ion influx required for generating an action potential, resulting in a temporary, localized interruption of impulse propagation.

Dosage and Administration Information

Tanflex, whose active ingredient is benzydamine, is administered via the oromucosal route through topical forms, including a mouthwash/gargle solution, an oromucosal spray, and lozenges. Standard usage involves specific dosage amounts and application methods.

Standard Labeled Dosing and Frequency

The standard regimens are intended for localized application and adherence to defined time limits. Dosage is measured per application, not total daily amount, and can be repeated as required by the schedule.

Formulation Standard Adult Dose Frequency Pattern
Mouthwash (0.15% w/v) 15 mL per dose Every 1.5 to 3 hours, as required
Oromucosal Spray 4 to 8 puffs per dose Every 1.5 to 3 hours, as required
Lozenges (3 mg) 1 lozenge Up to 3 times per day

Procedural Requirements and Duration

Proper administration is required. For the mouthwash solution, the liquid must be expelled after rinsing or gargling for 20 to 30 seconds; it is not to be swallowed. If local stinging occurs, the solution may be diluted with an equal volume of water prior to use. Lozenges must be allowed to dissolve slowly in the mouth and should not be chewed or swallowed whole. Uninterrupted treatment with any formulation should not exceed seven days unless a longer course is directed by a healthcare provider. If a lozenge dose is missed, the dose is typically skipped and the next dose is taken at the scheduled time.

Age-Specific Administration

Modified regimens are used for pediatric patients. For example, the oromucosal spray dosing for children 6 to 12 years of age is typically 4 puffs per application. The 0.15% mouthwash solution is generally not recommended for use in children aged 12 years and under. Older adults commonly receive the same dosage as the standard adult regimen.

Recent Clinical Evidence

Research evidence / Overview of Studies for Tanflex

Evidence for Use in Acute Sore Throat

Research exploring the topical use of benzydamine (Tanflex) consisted mainly of randomized controlled trials (RCTs) and systematic reviews. These studies were evaluated in adults experiencing acute episodes of throat pain. Research examined patient-reported outcomes describing perceived discomfort and used standardized scales to measure how symptoms change over time. The reported outcomes were generally focused on research exploring short-term symptom changes, often within the first 24 hours to one week.

Despite the existence of multiple trials, certainty remains low regarding consistency across the evidence landscape, especially when comparing different formulations. Evidence for sustained symptom measurement beyond one week is limited, and findings varied across studies in some older reviews looking at certain specific formulations.


Evidence for Use in Preventing Oral Mucositis

Benzydamine was studied for its role as a preventive measure against oral mucositis, a condition associated with functional limitations that may occur during cancer treatment. The evidence base includes high-level systematic reviews and meta-analyses. Research explored the use of the medicine in specific populations: adult patients with head and neck cancer receiving radiation therapy.

Major clinical guidelines describe consistent patterns observed in the studies, and research reports have contributed to documentation of the medicine's study for this prophylactic application. The data show patterns where the rate of occurrence of severe symptoms was observed to be lower in the studied populations, particularly among those receiving moderate radiation doses.

Limited information is available for patients receiving high-dose radiation therapy or when concurrent chemotherapy is being used alongside radiation. Furthermore, existing studies provide limited insight into the medicine's role for the treatment of mucositis once the condition is already established, as the research primarily focuses on its prevention.


What is Still Uncertain About the Evidence

The evidence highlights what is known and what is still uncertain. Data for certain groups remain insufficient, including for children in some contexts, and for patients with cancer receiving concurrent chemoradiation. Evidence quality varies across studies, particularly for the most common use in sore throat, where heterogeneity in study designs is noted. Long-term effects are not fully established, and there is limited information for long-term outcomes after the acute symptoms or treatments have concluded.

Key Studies & References

  1. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

Frequently Asked Questions (FAQ)

Common questions about Tanflex (FAQ)

Q: Is Tanflex the same as other pain-relieving mouthwashes?

A: Official information describes the active ingredient, benzydamine, as having a unique classification. It functions both as an atypical Nonsteroidal Anti-inflammatory Drug (NSAID) and as a local anesthetic (numbing agent). This dual action provides a specific pharmacological profile for local relief.

Q: Why is Tanflex prescribed or recommended by health professionals?

A: It is officially indicated for the symptomatic relief of pain and inflammation in the mouth and throat. This includes common conditions like acute sore throat and, in specific patient populations, for the prevention of radiation-induced oral mucositis.

Q: Does Tanflex only help with pain in the mouth and throat?

A: Yes, official indications and regulatory descriptions focus on its localized use for conditions affecting the mouth and throat (the oromucosal area). The various topical forms are specifically designed to deliver the therapeutic concentration directly to the site of pain, which minimizes systemic effects.

Q: How quickly can one generally expect Tanflex to start working?

A: Due to its local anesthetic properties, users often report a sensation of relief or numbing at the site of application. Official patient information leaflets often describe the onset of this effect as typically occurring within a few minutes of application.

Q: How long do the effects of Tanflex typically last?

A: The duration of symptomatic relief from a single application is defined by the regulatory dosing schedules. For some forms, official instructions suggest that symptomatic relief from one application may fall within a typical time frame of 1.5 to 3 hours.

Q: Are there different forms of Tanflex available (e.g., spray, mouthwash, lozenge)?

A: The medicine is officially available in several topical preparations for use in the mouth and throat. These include a mouthwash/gargle solution, an oromucosal spray, and lozenges.

Q: Can Tanflex be used for mouth sores or ulcers?

A: Official product information for various formulations often includes the symptomatic relief of pain associated with common mouth ulcers as one of the documented indications for use.

Q: Is Tanflex effective for sore throat from a cold or flu?

A: The medicine is indicated for the symptomatic relief of pain in acute sore throat. This indication covers those caused by local inflammatory conditions, including those associated with upper respiratory tract infections such as the common cold or flu.

Q: Does Tanflex cause drowsiness or affect alertness?

A: Official side effect lists for some formulations mention drowsiness as a possible, but generally infrequent, adverse reaction. Regulatory guidance generally suggests that the topical use of this medicine is unlikely to affect the ability to drive or operate machinery.

Q: Are there any specific foods or drinks that should be avoided when using Tanflex?

A: The regulatory information provided generally indicates that it is acceptable to eat and drink normally when using the product. Regulatory texts do not list specific foods or drinks that must be avoided due to a chemical interaction.

Q: Is it safe to use Tanflex if I am taking blood thinners?

A: Due to the very low systemic absorption of the topical formulations, official prescribing information reports a general absence of known, clinically significant systemic drug interactions. This profile indicates that systemic drug interactions with oral medicines, such as blood thinners (anticoagulants), are generally not expected to occur.

Q: Why do some people experience a bitter taste after using Tanflex?

A: A bitter taste or changes in taste sensation are listed among the possible adverse reactions reported in official product information. This is a recognized local effect that can occur due to the medicine's topical action in the mouth.

Q: Is Tanflex available without a prescription?

A: The legal classification can vary by country and formulation. In many countries, certain formulations are legally classified for over-the-counter (OTC) sale or are available from a pharmacist without a prescription.

Q: Does Tanflex have any sugar or alcohol content?

A: The excipient lists in official product documents for certain liquid formulations confirm the presence of Ethyl Alcohol (ethanol). Some formulations also use sweetening agents, such as Sorbitol, which is a sugar substitute.

Q: Are there any ingredients in Tanflex that might cause dental issues?

A: Some formulations may contain ingredients such as sugar substitutes. Official labels for the active ingredient alone do not commonly list dental issues; however, products combined with other compounds have documented warnings about potential effects like temporary teeth staining.

Q: Is it possible to become dependent on Tanflex if used frequently?

A: Regulatory risk assessments have been conducted regarding the potential for misuse. When the medicine is used at the labeled topical doses, it is not typically associated with dependence.

Q: Where can I find official, factual information about Tanflex?

A: Official, factual information about the medicine is contained in documents published by government agencies. This includes the Summary of Product Characteristics (SmPC), the Patient Information Leaflet (PIL), and regulatory drug registers in the country of sale.

Q: Can Tanflex be used if I have dentures or a dental implant?

A: Product information for the mouthwash formulation may specifically list the symptomatic relief of discomfort caused by local irritations. This can include irritation from dental hardware, such as dentures.

Q: Is the sensation of dryness in the mouth reported as a side effect?

A: Yes, official regulatory documents and patient information leaflets for some formulations include dryness of the mouth as a documented side effect.

Q: Has the safety of Tanflex been reviewed by regulatory bodies like the FDA or EMA?

A: Yes. The active ingredient has been evaluated and approved by many government health authorities around the world. Its safety profile is continually reviewed and monitored through bodies such as the EMA in Europe and various national agencies.

Q: Why is rinsing with water after use sometimes mentioned in online discussions?

A: Official usage instructions for the mouthwash formulation require that the solution must be expelled (spit out) after use. Furthermore, product information advises that if a local stinging sensation occurs, the solution can be diluted with an equal amount of water prior to use.

Q: Does using Tanflex affect my ability to swallow food or drink?

A: Due to its local anesthetic property (numbing effect), the medicine can cause temporary local numbness in the mouth and throat. Users are advised to be aware of this temporary sensation.

Q: Is it known if Tanflex can cause allergic skin reactions?

A: Official regulatory documents list systemic reactions among the very rare effects documented. These include potential for anaphylactic reaction (severe allergic reaction) and generalized hypersensitivity reactions affecting the skin and other body systems.

Q: Can Tanflex be used for irritation caused by orthodontic braces?

A: The medicine is indicated for the symptomatic relief of pain and irritation in the mouth. This use is generally applicable to various local inflammatory or irritative conditions of the oral cavity.

Q: Does the efficacy of Tanflex change if I accidentally swallow a small amount?

A: The mouthwash and spray formulations are explicitly labeled not to be swallowed as they are intended for local action. Accidental ingestion of small amounts is generally not expected to cause harm but may result in mild systemic side effects.

Q: Are there official warnings about the taste or sensation of Tanflex?

A: Yes. Official warnings and side effect lists include the potential for local effects. These effects include a bitter taste, a sensation of local stinging, and a temporary numbing sensation in the mouth or throat.

Q: Can Tanflex be used to help with pain from teething in infants?

A: Official guidance indicates that some topical forms of the active ingredient are used to help with symptoms related to teething in babies. Use in infants is formulation-dependent, often requiring specific pediatric dosing as outlined in the official product information.

Q: What does the research say about Tanflex's use after dental procedures?

A: Product information for the mouthwash formulation often includes the relief of pain after dental surgery as an indication for use. This is based on clinical data that supports its role in localized pain and inflammation management.

Q: Are there official warnings about combining Tanflex with other mouthwashes?

A: The official interaction profile provided in regulatory documents focuses on systemic drugs and herbal products. It does not specifically list warnings against combining it with other mouthwashes.

Q: Is Tanflex considered safe for use during pregnancy or breastfeeding?

A: Regulatory documents state that use is generally not recommended during pregnancy or lactation due to limited or insufficient data. Official guidance indicates that its use is conditional on physician assessment, as the professional must consider potential benefits against possible risks.

Q: Can Tanflex interact with common over-the-counter pain relievers?

A: Official regulatory information reports a general absence of known, clinically significant systemic drug interactions. This is due to the very low systemic absorption of the topical formulation, meaning it is unlikely to interact with common oral pain relievers.

Q: Can older adults or seniors use Tanflex without special precautions?

A: Official instructions indicate that older adults typically receive the same dosage as the standard adult regimen. This suggests that no special age-related precautions are universally mandated beyond those that apply to all adult users.

Q: Is Tanflex a steroid or does it contain antibiotics?

A: No. Official documents classify the medicine as an NSAID (Nonsteroidal Anti-inflammatory Drug) and a local anesthetic. The active ingredient is not a corticosteroid or an antibiotic.

How should Tanflex be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Tanflex (Benzydamine) are strictly defined by regulatory documents to maintain product stability and ensure public safety.

Storage Conditions

Constraint Official Regulatory Mandate
Temperature Do not store above 25 C or 30 C (varies by license); Do not refrigerate or freeze.
Container Store in the original package and keep the spray bottle in an upright position.
Child Safety Keep this medicine out of the sight and reach of children.
Stability Discard 6 months after the first opening of the container.

Disposal Instructions

Unused or expired product must not be thrown away via wastewater or household waste. Disposal must be performed in accordance with local requirements. Patients should consult a pharmacist for guidance on medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanflex found in:

A-Z Index: